The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia
Peptic Ulcer Bleeding, Hypoalbuminemia
About this trial
This is an interventional treatment trial for Peptic Ulcer Bleeding focused on measuring hypoalbuminemia, peptic ulcer, rebleeding, hospitalization
Eligibility Criteria
Inclusion Criteria:
- Clinical presentations of melena, hematochezia, or hematemesis
- Gastroscopy confirmed peptic ulcers and major stigmata of recent hemorrhage
- A Rockal score ≥ 6
Exclusion Criteria:
- Gastric or esophageal, or duodenal tumor bleeding
- Ulcer due to mechanical factors
- Warfarin use
- Failure to establish hemostasis under gastroscopy
- Hypersensitivity to omeprazole, esomeprazole, albumin or any component of the formulation.
Sites / Locations
- National Cheng Kung University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Normal albumin group
Intervention group
Cohort control group
Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L. Patients in this group receive intravenous omeprazole treatment.
Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L. Patients in this group receive both Human albumin and intravenous omeprazole.
The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group. Patients in this group receive intravenous omeprazole treatment.